Cargando…

Bone marrow mesenchymal stem cell-derived exosomal miR-34c-5p ameliorates RIF by inhibiting the core fucosylation of multiple proteins

Renal interstitial fibrosis (RIF) is an incurable pathological lesion in chronic kidney diseases. Pericyte activation is the major pathological characteristic of RIF. Fibroblast and macrophage activation are also involved in RIF. Studies have revealed that core fucosylation (CF), an important post-t...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Xuemei, Shen, Nan, Liu, Anqi, Wang, Weidong, Zhang, Lihua, Sui, Zhigang, Tang, Qingzhu, Du, Xiangning, Yang, Ning, Ying, Wantao, Qin, Biaojie, Li, Zhitong, Li, Lin, Wang, Nan, Lin, Hongli
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8821970/
https://www.ncbi.nlm.nih.gov/pubmed/34678513
http://dx.doi.org/10.1016/j.ymthe.2021.10.012
_version_ 1784646508566544384
author Hu, Xuemei
Shen, Nan
Liu, Anqi
Wang, Weidong
Zhang, Lihua
Sui, Zhigang
Tang, Qingzhu
Du, Xiangning
Yang, Ning
Ying, Wantao
Qin, Biaojie
Li, Zhitong
Li, Lin
Wang, Nan
Lin, Hongli
author_facet Hu, Xuemei
Shen, Nan
Liu, Anqi
Wang, Weidong
Zhang, Lihua
Sui, Zhigang
Tang, Qingzhu
Du, Xiangning
Yang, Ning
Ying, Wantao
Qin, Biaojie
Li, Zhitong
Li, Lin
Wang, Nan
Lin, Hongli
author_sort Hu, Xuemei
collection PubMed
description Renal interstitial fibrosis (RIF) is an incurable pathological lesion in chronic kidney diseases. Pericyte activation is the major pathological characteristic of RIF. Fibroblast and macrophage activation are also involved in RIF. Studies have revealed that core fucosylation (CF), an important post-translational modification of proteins, plays a key role in pericyte activation and RIF by regulating multiple profibrotic signaling pathways as a hub-like target. Here, we reveal that mesenchymal stem cell (MSC)-derived exosomes reside specifically in the injured kidney and deliver microRNA (miR)-34c-5p to reduce cellular activation and RIF by inhibiting CF. Furthermore, we showed that the CD81-epidermal growth factor receptor (EGFR) ligand-receptor complex aids the entry of exosomal miR-34c-5p into pericytes, fibroblasts, and macrophages. Altogether, our findings reveal a novel role of MSC-derived exosomes in inhibiting multicellular activation via CF and provide a potential intervention strategy for renal fibrosis.
format Online
Article
Text
id pubmed-8821970
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher American Society of Gene & Cell Therapy
record_format MEDLINE/PubMed
spelling pubmed-88219702023-02-02 Bone marrow mesenchymal stem cell-derived exosomal miR-34c-5p ameliorates RIF by inhibiting the core fucosylation of multiple proteins Hu, Xuemei Shen, Nan Liu, Anqi Wang, Weidong Zhang, Lihua Sui, Zhigang Tang, Qingzhu Du, Xiangning Yang, Ning Ying, Wantao Qin, Biaojie Li, Zhitong Li, Lin Wang, Nan Lin, Hongli Mol Ther Original Article Renal interstitial fibrosis (RIF) is an incurable pathological lesion in chronic kidney diseases. Pericyte activation is the major pathological characteristic of RIF. Fibroblast and macrophage activation are also involved in RIF. Studies have revealed that core fucosylation (CF), an important post-translational modification of proteins, plays a key role in pericyte activation and RIF by regulating multiple profibrotic signaling pathways as a hub-like target. Here, we reveal that mesenchymal stem cell (MSC)-derived exosomes reside specifically in the injured kidney and deliver microRNA (miR)-34c-5p to reduce cellular activation and RIF by inhibiting CF. Furthermore, we showed that the CD81-epidermal growth factor receptor (EGFR) ligand-receptor complex aids the entry of exosomal miR-34c-5p into pericytes, fibroblasts, and macrophages. Altogether, our findings reveal a novel role of MSC-derived exosomes in inhibiting multicellular activation via CF and provide a potential intervention strategy for renal fibrosis. American Society of Gene & Cell Therapy 2022-02-02 2021-10-19 /pmc/articles/PMC8821970/ /pubmed/34678513 http://dx.doi.org/10.1016/j.ymthe.2021.10.012 Text en © 2021 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original Article
Hu, Xuemei
Shen, Nan
Liu, Anqi
Wang, Weidong
Zhang, Lihua
Sui, Zhigang
Tang, Qingzhu
Du, Xiangning
Yang, Ning
Ying, Wantao
Qin, Biaojie
Li, Zhitong
Li, Lin
Wang, Nan
Lin, Hongli
Bone marrow mesenchymal stem cell-derived exosomal miR-34c-5p ameliorates RIF by inhibiting the core fucosylation of multiple proteins
title Bone marrow mesenchymal stem cell-derived exosomal miR-34c-5p ameliorates RIF by inhibiting the core fucosylation of multiple proteins
title_full Bone marrow mesenchymal stem cell-derived exosomal miR-34c-5p ameliorates RIF by inhibiting the core fucosylation of multiple proteins
title_fullStr Bone marrow mesenchymal stem cell-derived exosomal miR-34c-5p ameliorates RIF by inhibiting the core fucosylation of multiple proteins
title_full_unstemmed Bone marrow mesenchymal stem cell-derived exosomal miR-34c-5p ameliorates RIF by inhibiting the core fucosylation of multiple proteins
title_short Bone marrow mesenchymal stem cell-derived exosomal miR-34c-5p ameliorates RIF by inhibiting the core fucosylation of multiple proteins
title_sort bone marrow mesenchymal stem cell-derived exosomal mir-34c-5p ameliorates rif by inhibiting the core fucosylation of multiple proteins
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8821970/
https://www.ncbi.nlm.nih.gov/pubmed/34678513
http://dx.doi.org/10.1016/j.ymthe.2021.10.012
work_keys_str_mv AT huxuemei bonemarrowmesenchymalstemcellderivedexosomalmir34c5pamelioratesrifbyinhibitingthecorefucosylationofmultipleproteins
AT shennan bonemarrowmesenchymalstemcellderivedexosomalmir34c5pamelioratesrifbyinhibitingthecorefucosylationofmultipleproteins
AT liuanqi bonemarrowmesenchymalstemcellderivedexosomalmir34c5pamelioratesrifbyinhibitingthecorefucosylationofmultipleproteins
AT wangweidong bonemarrowmesenchymalstemcellderivedexosomalmir34c5pamelioratesrifbyinhibitingthecorefucosylationofmultipleproteins
AT zhanglihua bonemarrowmesenchymalstemcellderivedexosomalmir34c5pamelioratesrifbyinhibitingthecorefucosylationofmultipleproteins
AT suizhigang bonemarrowmesenchymalstemcellderivedexosomalmir34c5pamelioratesrifbyinhibitingthecorefucosylationofmultipleproteins
AT tangqingzhu bonemarrowmesenchymalstemcellderivedexosomalmir34c5pamelioratesrifbyinhibitingthecorefucosylationofmultipleproteins
AT duxiangning bonemarrowmesenchymalstemcellderivedexosomalmir34c5pamelioratesrifbyinhibitingthecorefucosylationofmultipleproteins
AT yangning bonemarrowmesenchymalstemcellderivedexosomalmir34c5pamelioratesrifbyinhibitingthecorefucosylationofmultipleproteins
AT yingwantao bonemarrowmesenchymalstemcellderivedexosomalmir34c5pamelioratesrifbyinhibitingthecorefucosylationofmultipleproteins
AT qinbiaojie bonemarrowmesenchymalstemcellderivedexosomalmir34c5pamelioratesrifbyinhibitingthecorefucosylationofmultipleproteins
AT lizhitong bonemarrowmesenchymalstemcellderivedexosomalmir34c5pamelioratesrifbyinhibitingthecorefucosylationofmultipleproteins
AT lilin bonemarrowmesenchymalstemcellderivedexosomalmir34c5pamelioratesrifbyinhibitingthecorefucosylationofmultipleproteins
AT wangnan bonemarrowmesenchymalstemcellderivedexosomalmir34c5pamelioratesrifbyinhibitingthecorefucosylationofmultipleproteins
AT linhongli bonemarrowmesenchymalstemcellderivedexosomalmir34c5pamelioratesrifbyinhibitingthecorefucosylationofmultipleproteins